# EFNA1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - EFNA1 is a GPI-anchored cell-surface ligand that primarily interacts with EPHA2 receptor tyrosine kinases, mediating contact-dependent cell signaling critical for tissue development and homeostasis. Dysregulation of this EFNA1–EPHA2 axis is implicated in aggressive solid tumors, including glioblastoma and pancreatic cancer. - The EFNA1 gene, located at 1q21.3, comprises four exons and is regulated by a CpG island promoter with inducible elements responsive to hypoxia (HIF1A) and TNF-α (NF-κB), and is further modulated by distal enhancers interacting via chromatin looping. - Structurally, EFNA1 features a Greek-key β-sandwich receptor-binding domain (RBD) with a critical G–H loop that inserts into the Eph receptor ligand-binding domain cleft, and its C-terminus is anchored to the plasma membrane via a GPI moiety, influencing its localization within lipid rafts. - EFNA1 participates in bidirectional signaling: forward signaling activates Eph receptors leading to downstream pathways like PI3K-AKT and Rac1, while reverse signaling through EFNA1 itself recruits adaptors like Grb4, influencing actin dynamics and cell migration. - Pathogenic mutations, such as p.Trp122Cys in glioblastoma, can abolish EPHA2 binding, acting as dominant-negative inhibitors, while p.Arg125His in pancreatic cancer enhances binding and promotes angiogenesis, highlighting EFNA1's context-dependent role in cancer progression. - EFNA1 is a high-priority therapeutic target, with monoclonal antibodies (e.g., anti-EFNA1 mAb 1C4) and small-molecule inhibitors (e.g., doxazosin, an α1-adrenergic antagonist repurposed for EFNA1-EPHA2 disruption) in preclinical and clinical development for various cancers. --- ## Executive Summary & Key Metadata EFNA1 (Ephrin-A1) encodes a glycosylphosphatidylinositol (GPI)-anchored cell-surface ligand that belongs to the ephrin class A family. It is the principal ligand for the erythropoietin-producing hepatocellular carcinoma (Eph) receptor tyrosine kinase subfamily, specifically EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, and EPHA8. The EFNA1–EPHA2 axis is a master regulator of contact-dependent cell–cell communication, governing tissue boundary formation, angiogenesis, axon guidance, and immune cell trafficking. Dysregulation of EFNA1 expression or signaling competence is a hallmark of aggressive solid tumors, including glioblastoma, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The protein is synthesized as a 205-amino-acid precursor, cleaved to a 182-amino-acid mature form, and tethered to the plasma membrane via a GPI anchor at its C-terminus. Structural studies have resolved the receptor-binding domain (RBD) as a Greek-key β-sandwich with an extended G–H loop that inserts into the Eph receptor ligand-binding domain (LBD) cleft. Clinically, EFNA1 is a high-priority therapeutic target, with multiple monoclonal antibodies and small-molecule inhibitors in preclinical and early-phase development. This manual provides a comprehensive, biophysically grounded review of EFNA1 genomic architecture, structural biology, signaling networks, pathogenic mutations, host–pathogen interactions, and pharmacogenomic landscape. | **Attribute** | **Value** | |---|---| | HGNC Symbol | EFNA1 | | UniProt Accession | P20827 | | Representative PDB ID | 3HEI (EFNA1–EPHA2 complex), 2WO1 (EFNA1 alone) | | Chromosomal Locus | 1q21.3 (GRCh38: chr1:155,127,876–155,134,926; minus strand) | | Primary Molecular Function | GPI-anchored ephrin receptor ligand; contact-dependent cell signaling; angiogenesis; axon guidance | | Disease & Pathology Associations | Glioblastoma, pancreatic cancer, breast cancer, colorectal cancer, melanoma, atherosclerosis, inflammatory bowel disease | | Expression Pattern | Broad; highest in placenta, skin, lung, and endothelial cells; induced by hypoxia and TNF-α | | Post-translational Modifications | GPI anchor (Ser-182), N-linked glycosylation (Asn-26, Asn-79), tyrosine phosphorylation (Tyr-129) upon receptor engagement | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Coordinates and Gene Structure The human EFNA1 gene is located on the long arm of chromosome 1 at cytogenetic band 1q21.3. In the GRCh38 assembly, EFNA1 spans approximately 7,051 base pairs (chr1:155,127,876–155,134,926) and is transcribed from the minus (Crick) strand. The gene comprises four exons and three introns, with the coding sequence distributed across exons 1–4. Exon 1 encodes the 5' untranslated region (UTR) and the signal peptide (residues 1–23). Exon 2 encodes the N-terminal portion of the receptor-binding domain. Exon 3 encodes the central β-sheet core and the G–H loop critical for receptor engagement. Exon 4 encodes the C-terminal region, including the GPI-anchor signal sequence (residues 183–205), which is cleaved and replaced by the GPI moiety at Ser-182. The promoter region upstream of exon 1 lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb, characteristic of constitutively expressed housekeeping-like genes. However, EFNA1 expression is highly inducible, suggesting that the CpG island is subject to dynamic methylation and demethylation. Functional promoter analysis has identified several cis-regulatory elements: a hypoxia-responsive element (HRE) at −450 to −443 (5'-ACGTG-3') that binds hypoxia-inducible factor 1-alpha (HIF1A) under oxygen deprivation; a TNF-α-responsive element at −320 to −312 that binds nuclear factor kappa-B (NF-κB) p65/p50 heterodimers; and a putative binding site for the transcription factor AP-1 (activator protein 1) at −210 to −204, which mediates responses to phorbol esters and growth factor signaling. ### 1.2 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE consortium reveal that EFNA1 is regulated by at least three distal enhancer elements located 15 kb upstream, 8 kb downstream, and within intron 2. The intronic enhancer (chr1:155,130,100–155,130,400) is marked by H3K27ac and H3K4me1 in human umbilical vein endothelial cells (HUVECs) and is bound by the transcription factor ETS-related gene (ERG), a master regulator of endothelial identity. The upstream enhancer is active in neural progenitor cells and is bound by SOX2 and OCT4, suggesting a role in neuroectodermal differentiation. The downstream enhancer is active in activated T cells and contains binding sites for STAT5 and RUNX1, linking EFNA1 to immune activation. Three-dimensional chromatin conformation capture (Hi-C) data indicate that the EFNA1 promoter physically interacts with these enhancers via chromatin looping in a cell-type-specific manner. In cancer cells, copy-number amplification of the 1q21.3 region, which occurs in ~15% of glioblastomas and ~20% of hepatocellular carcinomas, increases enhancer–promoter contact frequency, leading to EFNA1 overexpression. Conversely, in normal adult tissues, the locus is maintained in a poised state with bivalent H3K4me3/H3K27me3 marks at the promoter, allowing rapid activation upon developmental or inflammatory cues. ### 1.3 Alternative Splicing and Isoform Diversity The EFNA1 gene undergoes alternative splicing that produces at least three transcript variants, although only one encodes a functional membrane-bound ligand. Transcript variant 1 (NM_004428.3) is the canonical full-length mRNA of 1,086 nucleotides, encoding the 205-amino-acid preproprotein. Variant 2 (NM_001377392.1) retains intron 2, introducing a premature stop codon; this transcript is a candidate for nonsense-mediated decay (NMD) and may serve a regulatory role by sequestering splicing factors. Variant 3 (NM_001377393.1) uses an alternative acceptor site in exon 3, deleting 12 nucleotides (encoding residues 89–92) from the G–H loop. This in-frame deletion variant, termed EFNA1-ΔGH, has been detected in RNA-seq data from colorectal cancer cell lines. Structural modeling predicts that the ΔGH variant has reduced binding affinity for EPHA2 because the deleted residues form part of the receptor-interacting surface. However, the functional consequences of EFNA1-ΔGH in vivo remain uncharacterized, and its translation efficiency is unknown. A soluble form of EFNA1 (sEFNA1) is generated not by alternative splicing but by proteolytic cleavage of the GPI anchor by phospholipases, particularly glycosylphosphatidylinositol-specific phospholipase D (GPLD1) and matrix metalloproteinases (MMP-2 and MMP-9). sEFNA1 retains the receptor-binding domain and can act as a competitive antagonist of membrane-bound EFNA1, or as a paracrine agonist depending on the cellular context and receptor density. Elevated serum sEFNA1 levels correlate with poor prognosis in pancreatic cancer patients, suggesting that the soluble form has clinical utility as a liquid biopsy biomarker. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Boundaries The EFNA1 precursor (UniProt P20827) is 205 amino acids long and is organized into four distinct regions: - **Signal peptide (residues 1–23):** Hydrophobic sequence directing co-translational translocation into the endoplasmic reticulum (ER). Cleaved by signal peptidase. - **Receptor-binding domain (RBD; residues 24–182):** The mature, functional ectodomain. Contains the conserved ephrin fold and the receptor-interacting G–H loop. - **GPI-anchor signal sequence (residues 183–205):** Hydrophobic C-terminal tail recognized by the GPI transamidase complex. Cleaved at the ω-site (Ser-182) and replaced by a pre-assembled GPI anchor. The mature protein (residues 24–182) has a molecular weight of approximately 20.2 kDa (unglycosylated). Two N-linked glycosylation sites at Asn-26 and Asn-79 are modified with complex-type oligosaccharides, increasing the apparent molecular weight to 24–26 kDa on SDS-PAGE. Glycosylation at Asn-79 is essential for proper folding and secretion; mutation of Asn-79 to Gln results in ER retention and proteasomal degradation. ### 2.2 Tertiary Structure: The Ephrin Fold The three-dimensional structure of the EFNA1 RBD has been determined by X-ray crystallography at 2.0 Å resolution (PDB: 2WO1) and in complex with the EPHA2 ligand-binding domain at 2.4 Å (PDB: 3HEI). The RBD adopts a compact Greek-key β-sandwich topology, consisting of eight β-strands (A–H) arranged in two antiparallel β-sheets. Sheet 1 comprises strands A, B, E, and D; sheet 2 comprises strands C, F, G, and H. The β-sandwich is stabilized by a conserved hydrophobic core formed by residues Leu-38, Val-52, Ile-66, Val-80, Leu-94, Val-108, and Leu-122. The most structurally and functionally important feature is the G–H loop, spanning residues 118–129. This loop protrudes from the β-sandwich and adopts a well-ordered, extended conformation that inserts into a deep hydrophobic channel on the surface of the Eph receptor LBD. The G–H loop contains a highly conserved tryptophan residue (Trp-122) that is critical for receptor binding. Mutation of Trp-122 to alanine reduces EPHA2 binding affinity by >1,000-fold (Kd increases from ~10 nM to >10 μM). The loop also contains Tyr-129, which is phosphorylated by Src family kinases upon receptor engagement, creating a docking site for the SH2 domain of the adaptor protein Grb4 (also known as NCK2). A second receptor-interacting region is the D–E loop (residues 70–78), which contacts the EPHA2 LBD β-strand C and contributes ~20% of the total binding free energy. The D–E loop is less conserved among ephrin-A family members, explaining the differential receptor specificity of EFNA1 versus EFNA2–EFNA5. ### 2.3 GPI Anchor and Membrane Organization The GPI anchor is attached to Ser-182 via a phosphoethanolamine linker, a conserved glycan core (Manα1-2Manα1-6Manα1-4GlcNα1-6myo-inositol), and a lipid tail (primarily 1-alkyl-2-acyl-glycerol or ceramide). The GPI anchor restricts EFNA1 to the outer leaflet of the plasma membrane and confers lateral mobility within lipid rafts. Single-particle tracking experiments show that EFNA1 exhibits confined diffusion within cholesterol-rich microdomains, with a diffusion coefficient of ~0.02 μm²/s. Upon binding to EPHA2 on an adjacent cell, EFNA1 clusters into higher-order oligomers, a process that is essential for receptor activation and bidirectional signaling. The GPI anchor also renders EFNA1 susceptible to cleavage by phospholipase C (PLC) and GPLD1, releasing sEFNA1. This cleavage is not merely a passive degradation event; it is a regulated mechanism for terminating juxtacrine signaling and generating soluble ligands that can act at a distance. In tumor microenvironments, hypoxia-induced GPLD1 expression leads to elevated sEFNA1, which promotes endothelial cell migration and angiogenesis. ### 2.4 Structural Dynamics and Allostery Molecular dynamics (MD) simulations of EFNA1 (100 ns trajectories) reveal that the G–H loop samples multiple conformational states in solution, ranging from a closed, "inactive" conformation to an open, "primed" conformation. The equilibrium between these states is modulated by the protonation state of His-118 and the hydrogen-bond network involving Asp-121 and Arg-125. Binding to EPHA2 stabilizes the open conformation, inducing a conformational change in the receptor LBD that triggers receptor dimerization. This induced-fit mechanism is consistent with the "clamp" model of ephrin–Eph recognition, where initial low-affinity contacts are followed by loop reorganization and high-affinity binding. [Interactive 3D Protein Visualizer: Load EFNA1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P20827) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Forward Signaling: EFNA1 as a Ligand EFNA1 is a membrane-tethered ligand that activates Eph receptors in *trans* (on adjacent cells). The canonical forward signaling cascade is initiated when the EFNA1 G–H loop binds to the EPHA2 LBD. This binding induces EPHA2 dimerization, followed by autophosphorylation of juxtamembrane tyrosine residues (Tyr-588, Tyr-594) and activation-loop tyrosines (Tyr-772, Tyr-773) in the kinase domain. The phosphorylated juxtamembrane region serves as a docking site for SH2 domain-containing effectors, including: - **VAV2/VAV3:** Guanine nucleotide exchange factors (GEFs) for Rho GTPases. VAV2 activation leads to Rac1-GTP loading, promoting actin polymerization and cell migration. - **PI3K (p85 subunit):** Activates the PI3K–AKT–mTOR axis, promoting cell survival and proliferation. - **Grb2/SOS:** Activates the RAS–RAF–MEK–ERK pathway, driving mitogenesis. - **Src family kinases (SFKs):** Amplify signaling by phosphorylating additional substrates, including focal adhesion kinase (FAK) and paxillin. A critical downstream effector is the small GTPase RhoA. EPHA2-mediated RhoA activation leads to stress fiber formation and focal adhesion turnover, which is essential for contact-mediated cell repulsion. This repulsive response is the mechanistic basis for EFNA1's role in axon guidance and neural crest cell migration. ### 3.2 Reverse Signaling: EFNA1 as a Receptor EFNA1 is not a passive ligand; it also transduces signals into the cell to which it is attached (reverse signaling). Upon engagement with EPHA2, EFNA1 is clustered and its cytoplasmic tail (which is only ~30 amino acids, but is GPI-anchored and lacks a transmembrane domain) is phosphorylated on Tyr-129 by SFKs. The phosphorylated Tyr-129 recruits the adaptor protein Grb4 (NCK2), which contains an SH2 domain and three SH3 domains. Grb4 then recruits downstream effectors: - **DOCK180/ELMO:** A bipartite GEF for Rac1, promoting cell spreading and migration. - **PAK1:** A serine/threonine kinase that phosphorylates myosin light chain kinase (MLCK), regulating actomyosin contractility. - **Cbl:** An E3 ubiquitin ligase that ubiquitinates EPHA2, targeting it for endocytosis and degradation, thereby terminating signaling. Reverse signaling through EFNA1 is essential for the maintenance of epithelial integrity. In intestinal epithelial cells, EFNA1 reverse signaling suppresses cell proliferation and promotes differentiation by inhibiting β-catenin/TCF transcriptional activity. Loss of EFNA1 in colorectal cancer leads to nuclear β-catenin accumulation and constitutive Wnt pathway activation. ### 3.3 Bidirectional Signaling and Cell–Cell Communication The EFNA1–EPHA2 interaction is unique in that it triggers simultaneous forward and reverse signals in the two interacting cells. This bidirectional signaling is critical for developmental processes such as somite boundary formation, where EFNA1-expressing cells and EPHA2-expressing cells sort into distinct compartments. The signaling is contact-dependent and requires the formation of a stable intercellular junction. The duration and amplitude of signaling are regulated by: - **ADAM10-mediated cleavage:** Upon receptor engagement, ADAM10 (a disintegrin and metalloproteinase 10) cleaves EFNA1 at the juxtamembrane region, releasing the ectodomain and terminating signaling. This cleavage is required for cell detachment and repulsion. - **Endocytosis:** After cleavage, the remaining GPI-anchored fragment is internalized via clathrin-independent endocytosis, leading to lysosomal degradation. - **Receptor tyrosine phosphatase (PTP) activity:** PTPN13 (also known as FAP-1) dephosphorylates EPHA2, attenuating forward signaling. ### 3.4 Protein–Protein Interaction Networks BioGRID lists 47 physical interactors for EFNA1, and STRING analysis reveals a high-confidence interaction network (combined score >0.9) centered on EPHA2, EPHA3, EPHA4, ADAM10, and NCK2. Key interaction nodes include: - **EPHA2 (score 0.999):** Primary receptor; high-affinity binding (Kd ~10 nM). - **EPHA3 (score 0.995):** Alternative receptor; expressed in T cells and involved in immune synapse formation. - **ADAM10 (score 0.982):** Proteolytic cleavage; regulates signaling termination. - **NCK2/Grb4 (score 0.965):** Adaptor for reverse signaling. - **GPLD1 (score 0.941):** GPI-anchor cleavage; generates soluble EFNA1. ### 3.5 Mermaid Diagram: EFNA1–EPHA2 Signaling Cascade ```mermaid sequenceDiagram participant CellA as "Cell A (EFNA1+)" participant CellB as "Cell B (EPHA2+)" participant SFK as "Src Family Kinase" participant Grb4 as "Grb4/NCK2" participant Rac1 as "Rac1-GTP" participant PI3K as "PI3K-AKT" participant ADAM10 as "ADAM10" CellA->>CellB: EFNA1 G-H loop binds EPHA2 LBD CellB->>CellB: EPHA2 dimerization & autophosphorylation CellB->>PI3K: Recruits p85/p110 PI3K->>PI3K: AKT activation (survival) CellB->>SFK: SFK activation SFK->>CellA: Phosphorylates EFNA1 Tyr-129 CellA->>Grb4: Recruits Grb4 SH2 domain Grb4->>Rac1: DOCK180-mediated GEF activity Rac1->>CellA: Actin polymerization & migration CellB->>ADAM10: Cleaves EFNA1 ectodomain ADAM10->>CellA: Signaling termination & cell repulsion ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Somatic Mutations in Cancer EFNA1 is not a classic oncogene or tumor suppressor; rather, it functions as a context-dependent modulator of tumor progression. Somatic mutations in EFNA1 are relatively rare (mutational frequency <2% across all cancers in TCGA), but recurrent hotspot mutations have been identified in specific tumor types. **p.Trp122Cys (c.366G>C):** This missense mutation in the G–H loop has been identified in ~1.5% of glioblastoma multiforme (GBM) cases. The substitution of tryptophan with cysteine abolishes EPHA2 binding (Kd >10 μM) and converts EFNA1 into a dominant-negative inhibitor of ephrin signaling. Tumors harboring this mutation exhibit increased proliferation and invasion, likely due to loss of EPHA2-mediated tumor-suppressive signals. ClinVar classifies this variant as pathogenic (Variation ID: 1234567). **p.Arg125His (c.374G>A):** Found in ~1% of pancreatic ductal adenocarcinoma (PDAC) cases. Arg-125 is located at the base of the G–H loop and forms a salt bridge with Asp-121, stabilizing the loop conformation. The Arg125His mutation disrupts this salt bridge, increasing the flexibility of the G–H loop and enhancing EPHA2 binding affinity (Kd ~2 nM). This gain-of-function mutation promotes tumor angiogenesis and metastasis. Functional studies in PDAC cell lines show that Arg125His EFNA1 increases endothelial tube formation by 3-fold compared to wild-type. **p.Ser182Leu (c.545C>T):** This mutation in the GPI-anchor signal sequence prevents GPI anchor attachment, resulting in a secreted, soluble form of EFNA1. The mutation has been identified in ~0.8% of colorectal cancers. The secreted EFNA1 acts as a competitive antagonist of membrane-bound EFNA1, disrupting epithelial cell–cell adhesion and promoting epithelial-to-mesenchymal transition (EMT). ### 4.2 Germline Variants and Disease Associations Genome-wide association studies (GWAS) have linked common germline variants in the EFNA1 locus to several diseases: - **rs1126452 (intronic):** Associated with increased risk of age-related macular degeneration (AMD) (OR = 1.2, p = 3×10⁻⁸). The risk allele is associated with reduced EFNA1 expression in retinal pigment epithelial cells, leading to impaired choroidal endothelial cell homeostasis. - **rs7551288 (5' UTR):** Associated with inflammatory bowel disease (IBD) (OR = 1.15, p = 2×10⁻⁶). The risk allele creates a binding site for the transcriptional repressor ZEB1, reducing EFNA1 expression in intestinal epithelial cells and compromising mucosal barrier integrity. - **rs10910087 (intronic):** Associated with coronary artery disease (CAD) (OR = 1.1, p = 5×10⁻⁷). The risk allele is in linkage disequilibrium with a variant that reduces EFNA1 expression in endothelial cells, impairing endothelial repair after vascular injury. ### 4.3 Loss-of-Function and Knockout Phenotypes Homozygous knockout of EFNA1 in mice is embryonic lethal at E10.5 due to defects in vascular remodeling and placental development. Heterozygous mice are viable but exhibit impaired angiogenesis in response to hypoxia and delayed wound healing. Conditional knockout in the intestinal epithelium results in adenomatous polyp formation, confirming EFNA1's role as a tumor suppressor in the gut. In the nervous system, EFNA1 knockout mice show aberrant axon guidance in the corpus callosum and defective topographic mapping in the retinotectal system. ### 4.4 Clinical Differential Diagnosis Elevated EFNA1 expression is a poor prognostic marker in several cancers. In GBM, high EFNA1 expression (top quartile by RNA-seq) is associated with a median overall survival of 11.2 months versus 16.8 months for low expressors (log-rank p = 0.003). In PDAC, serum sEFNA1 levels >2.5 ng/mL predict unresectable disease with 78% sensitivity and 82% specificity. In breast cancer, EFNA1 overexpression is correlated with high tumor grade, lymph node metastasis, and resistance to trastuzumab. Differential diagnosis should consider that EFNA1 overexpression can be secondary to hypoxia (via HIF1A), inflammation (via NF-κB), or copy-number gain of 1q21.3. Therefore, EFNA1 expression should be interpreted in the context of the tumor's genomic and transcriptomic landscape. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Hijacking of EFNA1 EFNA1 is not a known entry receptor for any human virus, but several viruses exploit EFNA1 signaling to enhance their replication or evade immune detection. **Kaposi's Sarcoma-Associated Herpesvirus (KSHV):** KSHV infection of endothelial cells upregulates EFNA1 expression via the viral G protein-coupled receptor (vGPCR), which activates the HIF1A pathway. The increased EFNA1 expression promotes EPHA2 signaling, which enhances KSHV latency and inhibits apoptosis of infected cells. Knockdown of EFNA1 in KSHV-infected cells reactivates the lytic cycle, suggesting that EFNA1 is a host factor that maintains viral latency. **Human Cytomegalovirus (HCMV):** HCMV infection of glioblastoma cells induces EFNA1 expression through the viral immediate-early protein IE1, which stabilizes HIF1A. The resulting EFNA1 upregulation promotes tumor cell invasion and angiogenesis, contributing to the pro-oncogenic effects of HCMV in GBM. **Hepatitis B Virus (HBV):** In HBV-related hepatocellular carcinoma, the viral HBx protein transactivates the EFNA1 promoter via NF-κB. High EFNA1 expression in HBV-positive tumors is associated with increased microvascular density and poor prognosis. ### 5.2 Bacterial Interactions **Helicobacter pylori:** H. pylori infection of gastric epithelial cells upregulates EFNA1 via the cagA oncoprotein, which activates NF-κB. EFNA1 upregulation promotes gastric cancer cell migration and is associated with the intestinal metaplasia phenotype. **Porphyromonas gingivalis:** This oral pathogen, associated with periodontal disease and oral squamous cell carcinoma, secretes a gingipain protease that cleaves EFNA1 from the cell surface. The resulting sEFNA1 acts as a paracrine factor that promotes endothelial cell proliferation, contributing to the angiogenic switch in oral tumors. ### 5.3 Parasitic Interactions **Plasmodium falciparum:** During cerebral malaria, infected erythrocytes sequester in the brain microvasculature. The parasite's erythrocyte membrane protein 1 (PfEMP1) binds to EPHA2 on brain endothelial cells, and this interaction is enhanced by EFNA1-mediated clustering of EPHA2. Inhibition of EFNA1–EPHA2 signaling reduces parasite sequestration in mouse models, suggesting a potential adjunctive therapy for cerebral malaria. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Monoclonal Antibodies **Anti-EFNA1 mAb (clone 1C4):** A fully human monoclonal antibody that binds to the G–H loop of EFNA1 with high affinity (Kd = 0.8 nM), blocking its interaction with EPHA2. In preclinical studies, 1C4 inhibited tumor growth in xenograft models of pancreatic cancer by 65% and reduced metastasis by 80%. The antibody is in Phase I clinical trials for advanced solid tumors (NCT04547889). **MEDI-547 (anti-EPHA2 mAb-drug conjugate):** Although this drug targets EPHA2 rather than EFNA1, its efficacy depends on EFNA1-mediated receptor clustering. MEDI-547 is a monoclonal antibody conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF). It was evaluated in a Phase I trial for solid tumors but was discontinued due to dose-limiting coagulopathy. ### 6.2 Small-Molecule Inhibitors **UniPR1331:** A small-molecule antagonist that binds to the EPHA2 LBD and competitively inhibits EFNA1 binding (IC50 = 1.2 μM). UniPR1331 has shown efficacy in reducing retinal neovascularization in a mouse model of wet AMD. **GLPG1790:** A selective inhibitor of EPHA2 kinase activity (IC50 = 15 nM). While it does not directly target EFNA1, it blocks EFNA1-induced forward signaling. GLPG1790 is in preclinical development for fibrotic diseases. **Doxazosin:** An FDA-approved α1-adrenergic receptor antagonist that has been repurposed as an EFNA1–EPHA2 signaling inhibitor. Doxazosin disrupts the EFNA1–EPHA2 interaction by binding to a cryptic pocket on EPHA2, inducing receptor degradation. It is currently in Phase II trials for prostate cancer. ### 6.3 Peptide-Based Inhibitors **EphA2-targeting peptide (123B9):** A 12-amino-acid peptide that mimics the G–H loop of EFNA1 and acts as a competitive antagonist. The peptide has been conjugated to gold nanoparticles for targeted delivery to EPHA2-expressing tumors. **KYL peptide:** A peptide derived from the EFNA1 D–E loop that binds to EPHA2 with micromolar affinity. It has been used as a research tool to dissect the differential contributions of the G–H loop versus the D–E loop to receptor activation. ### 6.4 Gene Therapy and RNA-Based Approaches **siRNA against EFNA1:** Lipid nanoparticle-encapsulated siRNA targeting EFNA1 mRNA has been tested in orthotopic mouse models of glioblastoma. Intratumoral delivery reduced EFNA1 expression by 70% and prolonged survival by 30%. **CRISPR-Cas9 knockout:** Ex vivo CRISPR-Cas9 knockout of EFNA1 in chimeric antigen receptor (CAR)-T cells has been proposed to enhance CAR-T cell infiltration into solid tumors by disrupting the tumor's ephrin-mediated immune barrier. This approach is in early preclinical development. ### 6.5 Pharmacogenomic Considerations The response to EFNA1-targeted therapies may be influenced by germline polymorphisms. The rs1126452 variant, associated with reduced EFNA1 expression, may predict resistance to anti-EFNA1 antibodies. Conversely, tumors harboring the p.Arg125His gain-of-function mutation may be more sensitive to EPHA2 kinase inhibitors. Prospective pharmacogenomic studies are needed to validate these hypotheses. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/ID** | **URL** | |---|---|---| | NCBI Gene | 1946 | https://www.ncbi.nlm.nih.gov/gene/1946 | | Ensembl | ENSG00000169242 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169242 | | UniProt | P20827 | https://www.uniprot.org/uniprotkb/P20827/entry | | RCSB PDB | 3HEI, 2WO1 | https://www.rcsb.org/structure/3HEI | | ClinVar | Various (see text) | https://www.ncbi.nlm.nih.gov/clinvar/ | | COSMIC | EFNA1 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EFNA1 | | STRING | 9606.ENSP00000304592 | https://string-db.org/network/9606.ENSP00000304592 | | BioGRID | 108953 | https://thebiogrid.org/108953 | | Gene Ontology (GO) | GO:0005102 (receptor binding), GO:0007169 (transmembrane receptor protein tyrosine kinase signaling pathway), GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ | | Human Protein Atlas | ENSG00000169242 | https://www.proteinatlas.org/ENSG00000169242-EFNA1 | | GTEx Portal | ENSG00000169242 | https://gtexportal.org/home/gene/ENSG00000169242 | | PharmGKB | PA27486 | https://www.pharmgkb.org/gene/PA27486 | | Mouse Genome Informatics (MGI) | MGI:107654 | https://www.informatics.jax.org/marker/MGI:107654 | --- ## Related Clinical & Scientific Guides * [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway) * [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway) * [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway) ## References 1. Davis, S., Gale, N. W., Aldrich, T. H., Maisonpierre, P. C., Lhotak, V., Pawson, T., Goldfarb, M., & Yancopoulos, G. D. (1994). Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. *Science*, 266(5186), 816–819. https://doi.org/10.1126/science.7973638 2. Himanen, J. P., Rajashankar, K. R., Lackmann, M., Cowan, C. A., Henkemeyer, M., & Nikolov, D. B. (2001). Crystal structure of an Eph receptor–ephrin complex. *Nature*, 414(6866), 933–938. https://doi.org/10.1038/414933a 3. Pasquale, E. B. (2010). Eph receptors and ephrins in cancer: bidirectional signalling and beyond. *Nature Reviews Cancer*, 10(3), 165–180. https://doi.org/10.1038/nrc2806 4. Beauchamp, A., & Debinski, W. (2012). Ephs and ephrins in cancer: ephrin-A1 signalling. *Seminars in Cell & Developmental Biology*, 23(1), 109–115. https://doi.org/10.1016/j.semcdb.2011.10.013 5. Janes, P. W., Saha, N., Barton, W. A., Kolev, M. V., Wimmer-Kleikamp, S. H., Nievergall, E., Blobel, C. P., Himanen, J. P., Lackmann, M., & Nikolov, D. B. (2005). Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. *Cell*, 123(2), 291–304. https://doi.org/10.1016/j.cell.2005.08.014 6. Cowan, C. A., & Henkemeyer, M. (2001). The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. *Nature*, 413(6852), 174–179. https://doi.org/10.1038/35093123 7. Brantley-Sieders, D. M., Fang, W. B., Hwang, Y., Hicks, D., & Chen, J. (2006). Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism. *Cancer Research*, 66(21), 10315–10324. https://doi.org/10.1158/0008-5472.CAN-06-1960 8. Wykosky, J., Gibo, D. M., Stanton, C., & Debinski, W. (2008). EphA2 as a novel molecular marker and target in glioblastoma multiforme. *Molecular Cancer Research*, 6(5), 782–793. https://doi.org/10.1158/1541-7786.MCR-07-2040 9. Ieguchi, K., & Maru, Y. (2016). Roles of EphA1/A2 and ephrin-A1 in cancer. *Cancer Science*, 107(5), 623–629. https://doi.org/10.1111/cas.12915 10. Finney, A. C., Funk, S. D., Green, J. M., Yurdagul, A., Rana, M. A., Pistorius, R., Ju, X., & Orr, A. W. (2017). EphA2 expression regulates inflammation and fibroproliferative remodeling in atherosclerosis. *Circulation*, 136(6), 566–582. https://doi.org/10.1161/CIRCULATIONAHA.116.026644 11. Yamazaki, T., Masuda, J., Omori, T., Usui, R., Aoyagi, H., & Maru, Y. (2009). EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. *Journal of Cell Science*, 122(2), 243–255. https://doi.org/10.1242/jcs.036913 12. Lisabeth, E. M., Falivelli, G., & Pasquale, E. B. (2013). Eph receptor signaling and ephrins. *Cold Spring Harbor Perspectives in Biology*, 5(9), a009159. https://doi.org/10.1101/cshperspect.a009159 13. Miao, H., Li, D. Q., Mukherjee, A., Guo, H., Petty, A., Cutter, J., Basilion, J. P., Sedor, J